C-reactive protein: A biomarker of survival in patients with localized upper tract urothelial carcinoma treated with radical nephroureterectomy

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 8, 2013, Pages 1725-1730

  Obata, Jun ^a   Kikuchi, Eiji ^a   Tanaka, Nobuyuki ^a   Matsumoto, Kazuhiro ^a   Hayakawa, Nozomi ^a   Ide, Hiroki ^a   Miyajima, Akira ^a   Nakagawa, Ken ^a   Oya, Mototsugu ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

C reactive protein; Cancer; Prognosis; Survival; Upper tract urothelial carcinoma

Indexed keywords

C REACTIVE PROTEIN; CISPLATIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CYSTOSCOPY; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS UROGRAPHY; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; NEPHROURETERECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; TRANSITIONAL CELL CARCINOMA; URINE CYTOLOGY;

C-REACTIVE PROTEIN; CANCER; PROGNOSIS; SURVIVAL; UPPER TRACT UROTHELIAL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CARCINOMA, TRANSITIONAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEPHRECTOMY; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; URETER; URINARY TRACT; UROLOGIC NEOPLASMS;

EID: 84886253590     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.05.008     Document Type: Article

References (30)

1. Holmäng S., Johansson S.L. Urothelial carcinoma of the upper urinary tract: Comparison between the WHO/ISUP 1998 consensus classification and WHO 1999 classification system. Urology 2005, 66:274-278.
2. Zigeuner R., Pummer K. Urothelial carcinoma of the upper urinary tract: Surgical approach and prognostic factors. Eur Urol 2008, 53:720-731.
3. Rouprêt M., Zigeuner R., Palou J., et al. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol 2011, 59:584-594.
4. Favaretto R.L., Shariat S.F., Chade D.C., et al. The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol 2010, 58:574-580.
5. Margulis V., Shariat S.F., Matin S.F., et al. Outcomes of radical nephroureterectomy: A series from the upper tract urothelial carcinoma collaboration. Cancer 2009, 115:1224-1233.
6. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
7. Balkwill F., Mantovani A. Inflammation and cancer: Back to Virchow?. Lancet 2001, 357:539-545.
8. Nozoe T., Matsumata T., Kitamura M., et al. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 1998, 176:335-338.
9. Forrest L.M., McMillan D.C., McArdle C.S., et al. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer 2004, 90:1704-1706.
10. Al Murri, Bartlett J.M., Canney P.A., et al. Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer 2006, 94:227-230.
11. Hashimoto K., Ikeda Y., Korenaga D., et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 2005, 103:1856-1864.
12. Guillem P., Triboulet J.P. Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer. Dis Esophagus 2005, 18:146-150.
13. Kodama J., Miyagi Y., Seki N., et al. Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1999, 82:107-110.
14. Gakis G., Todenhöfer T., Renninger M., et al. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: The TNR-C score. BJU Int 2011, 108:1800-1805.
15. Yoshida S., Saito K., Koga F., et al. C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy. BJU Int 2008, 101:978-981.
16. Saito K., Kawakami S., Ohtsuka Y., et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int 2007, 100:269-273.
17. Kinoshita T., Ito H., Miki C. Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer 1999, 85:2526-2531.
18. McKeown D.J., Brown D.J., Kelly A., et al. The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer. Br J Cancer 2004, 91:1993-1995.
19. Okamoto M., Hattori K., Oyasu R. Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro. Int J Cancer 1997, 72:149-154.
20. Jee S.H., Shen S.C., Chiu H.C., et al. Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency. Oncogene 2001, 20:198-208.
21. Trikha M., Corringham R., Klein B., et al. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: A review of the rationale and clinical evidence. Clin Cancer Res 2003, 9:4653-4665.
22. Du Clos T.W., Mold C. C-reactive protein: An activator of innate immunity and a modulator of adaptive immunity. Immunol Res 2004, 30:261-277.
23. Macciò A., Lai P., Santona M.C., et al. High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. Gynecol Oncol 1998, 69:248-252.
24. Canna K., McArdle P.A., McMillan D.C., et al. The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer 2005, 92:651-654.
25. McMillan D.C., Scott H.R., Watson W.S., et al. Longitudinal study of body cell mass depletion and the inflammatory response in cancer patients. Nutr Cancer 1998, 31:101-105.
26. Kotler D.P. Cachexia. Ann Intern Med 2000, 133:622-634.
27. Casamassima A., Picciariello M., Quaranta M., et al. C-reactive protein: A biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol 2005, 173:52-55.
28. Saito K., Tatokoro M., Fujii Y., et al. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur Urol 2009, 55:1145-1153.
29. Hilmy M., Bartlett J.M., Underwood M.A., et al. The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer 2005, 92:625-627.
30. Andrews B., Shariat S.F., Kim J.H., et al. Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. J Urol 2002, 167:1475-1481.